A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Stopped Due to a strategic reprioritization based on the rapidly changing clinical and commercial landscape for Bruton's tyrosine kinase inhibitors (BTK inhibitors)
Conditions
- Lymphoma, Mantle-Cell
- Lymphoma
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Immune System Diseases
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
Interventions
- DRUG: Zilovertamab
- DRUG: Ibrutinib
- DRUG: Placebo
Sponsor
Oncternal Therapeutics, Inc
Collaborators